These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9219039)

  • 1. Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas.
    Reed GL
    Hybridoma; 1997 Jun; 16(3):281-6. PubMed ID: 9219039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
    Butte AN; Houng AK; Jang IK; Reed GL
    Circulation; 1997 Apr; 95(7):1886-91. PubMed ID: 9107177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of monoclonal antibodies in the diagnosis of fibrinolysis].
    Wojta J; Korninger C; Kirchheimer J; Hattey E; Turcu L; Binder BR
    Wien Klin Wochenschr; 1985 Mar; 97(5):244-8. PubMed ID: 4039506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate.
    Sazonova IY; Thomas BM; Gladysheva IP; Houng AK; Reed GL
    J Thromb Haemost; 2007 Oct; 5(10):2087-94. PubMed ID: 17883703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
    Kurokawa T; Iwasa S; Kakinuma A
    Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preparation and characterization of monoclonal antibodies against human plasmin-alpha 2-antiplasmin complexes].
    Li JX; Wang H; Hang Q; Zheng ZY; Luo W; Li D; Wang HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):372-5. PubMed ID: 15193242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.
    Abdul S; Peeters M; Brouwers E; Malfliet JJMC; Leebeek FWG; Declerck PJ; Rijken DC; Uitte de Willige S
    PLoS One; 2018; 13(5):e0196911. PubMed ID: 29723259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
    Ogloblina OG; Saburova OS; Semenova OA; Belova LA
    Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C; Collen D
    Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies against plasma protease inhibitors: I. Production and characterization of 23 monoclonal antibodies against human alpha 2-antiplasmin.
    Herion P; Siberdt D; Garduno Soto G; Urbain J; Bollen A
    Biosci Rep; 1984 Jan; 4(1):39-48. PubMed ID: 6199051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
    Gargan PE; Ploplis VA; Scheu JD
    Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope mapping of human follicle stimulating hormone-alpha using monoclonal antibody 3A identifies a potential receptor binding sequence.
    Weiner RS; Dias JA; Andersen TT
    Endocrinology; 1991 Mar; 128(3):1485-95. PubMed ID: 1705506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and characterization of monoclonal antibodies to the human thyrotropin (TSH) receptor: antibodies can bind to discrete conformational or linear epitopes and block TSH binding.
    Seetharamaiah GS; Wagle NM; Morris JC; Prabhakar BS
    Endocrinology; 1995 Jul; 136(7):2817-24. PubMed ID: 7540542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
    Cucuianu M; Knauer O; Roman S
    Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.